SAN DIEGO–(BUSINESS WIRE)–BTS Research announced today that they have appointed Ian Dean as their VP of Toxicology. Ian has over 27 years in the nonclinical contract research industry, with experience across UK, Canada, Asia and the US.
In addition, Ian had various responsibilities in previous CRO’s such as Huntingdon Research Centre (now Envigo), Inveresk Research International (now Charles River), ITR, Southern Research Institute, LAB (now CiToxLab) and Primetrics – Singapore. In addition, Ian has spent 10 years as an independent regulatory consultant and was an Expert External Reviewer for Health Canada’s New Drug Submissions. Ian has extensive preclinical and clinical expertise spanning protocol design, study oversight, regulatory gap analysis, audit of nonclinical and clinical bioanalysis facilities, and preparing regulatory documentation. He is a Diplomate of the Institute of Biology in Toxicology (DIBT) and a Diplomate of the American Board of Toxicology (DABT; 1995-2015).
Ian and a group of Senior Scientists and Study Directors that have been hired over the last six months at BTS are now able to cover the increasing demand for study and program oversight.
“BTS Research is now much more prepared to take on multiple programs and maintain the quality and speed expected by its clients,” BTS President & CEO Sami Abunadi commented. “We are pleased to have Ian join us along with the fantastic new and talented in vitroand in vivo scientists who have proven track record to meet this increasing demand. With the recent expansions in the lab and vivarium space, we had to increase our scientific base to be able to execute with speed and quality,” Mr. Abunadi added.
About BTS Research
BTS is a San Diego based Contract Research Organization (“CRO”) that delivers GLP and Non-GLP biological services to large and small clients in pharmaceutical/biopharmaceutical, biotech, academic research and medical device organizations in the areas of Inflammation, Metabolic Disease, Cancer, Stem Cell and Medical Devices since 2001. BTS Research is a recognized leader in providing global preclinical solutions in all regulated species from early discovery to IND enabling studies.